1
|
Cui Y and Jia J: Update on epidemiology of
hepatitis B and C in China. J Gastroenterol Hepatol. 28(Suppl 1):
7–10. 2013. View Article : Google Scholar : PubMed/NCBI
|
2
|
Lauer GM and Walker BD: Hepatitis C virus
infection. N Engl J Med. 345:41–52. 2001. View Article : Google Scholar : PubMed/NCBI
|
3
|
El-Serag HB, Hampel H, Yeh C and Rabeneck
L: Extrahepatic manifestations of hepatitis C among United States
male veterans. Hepatology. 36:1439–1445. 2002. View Article : Google Scholar : PubMed/NCBI
|
4
|
Andrade LJ, Atta AM, D’Almeida Junior A
and Paraná R: Thyroid dysfunction in hepatitis C individuals
treated with interferon-alpha and ribavirin - a review. Braz J
Infect Dis. 12:144–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
5
|
Antonelli A, Ferri C, Fallahi P, Ferrari
SM, Ghinoi A, Rotondi M and Ferrannini E: Thyroid disorders in
chronic hepatitis C virus infection. Thyroid. 16:563–572. 2006.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Tomer Y, Blackard JT and Akeno N:
Interferon alpha treatment and thyroid dysfunction. Endocrinol
Metab Clin North Am. 36:1051–1166. x–xi. 2007. View Article : Google Scholar : PubMed/NCBI
|
7
|
Vezali E, Elefsiniotis I, Mihas C,
Konstantinou E and Saroglou G: Thyroid dysfunction in patients with
chronic hepatitis C: virus- or therapy-related? J Gastroenterol
Hepatol. 24:1024–1029. 2009. View Article : Google Scholar : PubMed/NCBI
|
8
|
Antonelli A, Ferri C, Pampana A, Fallahi
P, Nesti C, Pasquini M, Marchi S and Ferrannini E: Thyroid
disorders in chronic hepatitis C. Am J Med. 117:10–13. 2004.
View Article : Google Scholar
|
9
|
Nair Kesavachandran C, Haamann F and
Nienhaus A: Frequency of thyroid dysfunctions during interferon
alpha treatment of single and combination therapy in hepatitis C
virus-infected patients: a systematic review based analysis. PLoS
One. 8:e553642013.
|
10
|
Danilovic DL, Mendes-Correa MC, Chammas
MC, Zambrini H, Barros RK and Marui S: Thyroid disturbance related
to chronic hepatitis C infection: role of CXCL10. Endocr J.
60:583–590. 2013. View Article : Google Scholar : PubMed/NCBI
|
11
|
Tran A, Quaranta JF, Benzaken S, Thiers V,
Chau HT, Hastier P, Regnier D, Dreyfus G, Pradier C, Sadoul JL, et
al: High prevalence of thyroid autoantibodies in a prospective
series of patients with chronic hepatitis C before interferon
therapy. Hepatology. 18:253–257. 1993. View Article : Google Scholar : PubMed/NCBI
|
12
|
Rodríguez-Torres M, Ríos-Bedoya CF,
Ortiz-Lasanta G, Marxuach-Cuétara AM and Jiménez-Rivera J: Thyroid
dysfunction (TD) among chronic hepatitis C patients with mild and
severe hepatic fibrosis. Ann Hepatol. 7:72–77. 2008.PubMed/NCBI
|
13
|
Surks MI, Ortiz E, Daniels GH, Sawin CT,
Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA,
Gorman C, Cooper RS and Weissman NJ: Subclinical thyroid disease:
scientific review and guidelines for diagnosis and management.
JAMA. 291:228–238. 2004. View Article : Google Scholar : PubMed/NCBI
|
14
|
Khairy M, El-Raziky M, El-Akel W,
Abdelbary MS, Khatab H, El-Kholy B, Esmat G and Mabrouk M: Serum
autoantibodies positivity prevalence in patients with chronic HCV
and impact on pegylated interferon and ribavirin treatment
response. Liver Int. 33:1504–1509. 2013.PubMed/NCBI
|
15
|
Yang DH, Ho LJ and Lai JH: Useful
biomarkers for assessment of hepatitis C virus infection-associated
autoimmune disorders. World J Gastroenterol. 20:2962–2970. 2014.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Oliveira-Filho AB, Sawada L, Pinto LC,
Locks D, Bahia SL, Castro JA, Hermes RB, Brasil-Costa I, Amaral CE
and Lemos JA: Epidemiological aspects of HCV infection in
non-injecting drug users in the Brazilian state of Pará, eastern
Amazon. Virol J. 11:382014.PubMed/NCBI
|
17
|
Singh P, Kaur R and Kaur A: Frequency
distribution of Hepatitis C virus in different geographical regions
of Punjab: Retrospective study from a tertiary care centre in North
India. J Nat Sci Biol Med. 5:56–58. 2014. View Article : Google Scholar : PubMed/NCBI
|
18
|
Viazov S, Zibert A, Ramakrishnan K, Widell
A, Cavicchini A, Schreier E and Roggendorf M: Typing of hepatitis C
virus isolates by DNA enzyme immunoassay. J Virol Methods.
48:81–91. 1994. View Article : Google Scholar : PubMed/NCBI
|
19
|
Sibbing B and Nattermann J: Hepatitis C
virus infection and genetic susceptibility to therapy. J
Gastrointestin Liver Dis. 20:397–406. 2011.PubMed/NCBI
|
20
|
Zeuzem S, Berg T, Moeller B, Hinrichsen H,
Mauss S, Wedemeyer H, Sarrazin C, Hueppe D, Zehnter E and Manns MP:
Expert opinion on the treatment of patients with chronic hepatitis
C. J Viral Hepat. 16:75–90. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ploix C, Verber S, Chevallier - Queyron P,
Ritter J, Bousset G, Monier JC and Fabien N: Hepatitis C virus
infection is frequently associated with high titers of anti-thyroid
antibodies. Int J Immunopathol Pharmacol. 12:121–126.
1999.PubMed/NCBI
|
22
|
Yang R, Shan Z, Li Y, Fan C, Li C and Teng
W: Prevalence of thyroid autoantibodies in hepatitis C and
hepatitis B infection in China. Intern Med. 50:811–815. 2011.
View Article : Google Scholar : PubMed/NCBI
|
23
|
Danilovic DL, Mendes-Correa MC, Chammas
MC, Zambrini H, Barros RK and Marui S: Thyroid disturbance related
to chronic hepatitis C infection: role of CXCL10. Endocr J.
60:583–590. 2013. View Article : Google Scholar : PubMed/NCBI
|
24
|
Dalgard O, Bjøro K, Hellum K, Myrvang B,
Bjøro T, Haug E and Bell H: Thyroid dysfunction during treatment of
chronic hepatitis C with interferon alpha: no association with
either interferon dosage or efficacy of therapy. J Intern Med.
251:400–406. 2002. View Article : Google Scholar : PubMed/NCBI
|
25
|
Friedrich-Rust M, Theobald J, Zeuzem S and
Bojunga J: Thyroid function and changes in ultrasound morphology
during antiviral therapy with pegylated interferon and ribavirin in
patients with chronic hepatitis C. J Viral Hepat. 16:168–177. 2009.
View Article : Google Scholar
|
26
|
Andrade LJ, Atta AM, D’Almeida Junior A
and Paraná R: Thyroid dysfunction in hepatitis C individuals
treated with interferon-alpha and ribavirin - a review. Braz J
Infect Dis. 12:144–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
27
|
Chirico V, Antonio L, Vincenzo S, Luca N,
Valeria F, Basilia P, Luciana R, Carmelo S and Teresa A: Thyroid
dysfunction in thalassaemic patients: ferritin as a prognostic
marker and combined iron chelators as an ideal therapy. Eur J
Endocrinol. 170:X32014. View Article : Google Scholar : PubMed/NCBI
|
28
|
Tao YL, Tang YF, Qiu JP, Cai XF, Shen XT,
Wang YX and Zhao XT: Prevalence of hepatitis C infection among
intravenous drug users in Shanghai. World J Gastroenterol.
19:5320–5325. 2013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Hsieh MC, Yu ML, Chuang WL, Shin SJ, Dai
CY, Chen SC, Lin ZY, Hsieh MY, Liu JF, Wang LY and Chang WY:
Virologic factors related to interferon-alpha-induced thyroid
dysfunction in patients with chronic hepatitis C. Eur J Endocrinol.
142:431–437. 2000. View Article : Google Scholar : PubMed/NCBI
|
30
|
Cappola AR, Fried LP, Arnold AM, Danese
MD, Kuller LH, Burke GL, Tracy RP and Ladenson PW: Thyroid status,
cardiovascular risk, and mortality in older adults. JAMA.
295:1033–1041. 2006. View Article : Google Scholar : PubMed/NCBI
|